nach oben

Current Allergy and Asthma Reports

Erschienen in:

01.03.2010

Allergic Conjunctivitis and the Impact of Allergic Rhinitis

verfasst von: Leonard Bielory

Erschienen in: Current Allergy and Asthma Reports | Ausgabe 2/2010

Einloggen, um Zugang zu erhalten

Abstract

Although nasal allergy has been prominent in allergy research, ocular allergy is increasingly recognized as a distinct symptom complex that imposes its own disease burden and reduction in patients’ quality of life. In the past year, knowledge of the relationships between allergic conjunctivitis and allergic rhinitis has increased. Allergic conjunctivitis is highly prevalent and has a close epidemiologic relationship with allergic rhinitis. Both conditions also exhibit similar pathophysiologic mechanisms. Pathways of communication are thought to increase the likelihood of an inflammatory reaction at both sites following allergen exposure of nasal or ocular tissue. Clinical trials of intranasal therapies have demonstrated efficacy in allergic conjunctivitis and rhinitis. Newer intranasal steroids decrease ocular symptoms, potentially achieving efficacy by suppressing the naso-ocular reflex, downregulation of inflammatory cell expression, or restoration of nasolacrimal duct patency. Proposed pathophysiologic interactions between allergic rhinitis and ocular allergy underscore the need for therapies with efficacy in both symptom sets.

Meltzer EO, Nathan R, Derebery J, et al. Sleep, quality of life, and productivity impact of nasal symptoms in the United States: findings from the Burden of Rhinitis in America survey. Allergy Asthma Proc 2009;30:244–54.PubMedCrossRef

Bielory L. Allergic diseases of the eye. Med Clin North Am 2006;90:129–48.PubMedCrossRef

Pitt AD, Smith AF, Lindsell L, et al. Economic and quality-of-life impact of seasonal allergic conjunctivitis in Oxfordshire. Ophthalmic Epidemiol 2004;11:17–33.PubMedCrossRef

Buchholz PM, Wlat J, Lorenz D, et al. Patient impact of allergic conjunctivitis as measured by the Eye Allergy Patient Impact Questionnaire (EAPIQ) [poster B438]. Poster presented at the Association for Research in Vision and Ophthalmology. Fort Lauderdale, FL; May 7, 2003.

Smith AF, Pitt AD, Rodruiguez AE, et al. The economic and quality of life impact of seasonal allergic conjunctivitis in a Spanish setting. Ophthalmic Epidemiol 2005;12:233–42.PubMedCrossRef

Uchio E, Kimura R, Migita H, et al. Demographic aspects of allergic ocular diseases and evaluation of new criteria for clinical assessment of ocular allergy. Graefes Arch Clin Exp Ophthalmol 2008;246:291–6.PubMedCrossRef

Nathan RA, Meltzer EO, Selner JC, Storms W. Prevalence of allergic rhinitis in the United States. J Allergy Clin Immunol 1997;99:S808–814.CrossRef

Nathan RA, Meltzer EO, Derebery J, et al. The prevalence of nasal symptoms attributed to allergies in the United States: findings from the Burden of Rhinitis in America survey. Allergy Asthma Proc 2008;29:600–608.PubMedCrossRef

European Community Respiratory Health Survey. Variations in the prevalence of respiratory symptoms, self-reported asthma attacks, and use of asthma medication in the European Community Respiratory Health Survey (ECRHS). Eur Respir J 1996;9:687–95.CrossRef

10.

Singh K, Bielory L. Epidemiology of ocular allergy symptoms in United States adults (1988–1994) [abstract 34]. Abstract presented at the American College of Allergy, Asthma & Immunology Annual Meeting. Philadelphia, PA; November 9–15, 2006.

11.

Wüthrich B, Brignoli R, Canevascini M, Gerber M. Epidemiological survey in hay fever patients: symptom prevalence and severity and influence on patient management. Schweiz Med Wochenschr 1998;128:139–43.PubMed

12.

Klossek JM, Annesi-Maesano I, Pribil C, Didier A. INSTANT: national survey of allergic rhinitis in a French adult population based-sample. Presse Med 2009;38:1220–29.PubMedCrossRef

13.

Navarro A, Colás C, Antón E, et al. Rhinoconjunctivitis Committee of the SEAIC: epidemiology of allergic rhinitis in allergy consultations in Spain. J Investig Allergol Clin Immunol 2009;19(Suppl 2):7–13.PubMed

14.

Axelrod SH, Singh K, Bielory L. Epidemiology of ocular allergy: an NHANES III data review, 1988–1994 [abstract 484]. J Allergy Clin Immunol 2009;123:S127.CrossRef

15.

• Pelikan Z. Seasonal and perennial allergic conjunctivitis: the possible role of nasal allergy. Clin Experiment Ophthalmol 2009;37:448–57. This was an interesting study reflecting that more than 80% of positive nasal provocation with allergens induced an ocular response, thus supporting the concept of the naso-ocular reflex. CrossRef

16.

Aït-Khaled N, Pearce N, Anderson HR, et al. the ISAAC Phase Three Study Group: global map of the prevalence of symptoms of rhinoconjunctivitis in children: the International Study of Asthma and Allergies in Childhood (ISAAC) phase three. Allergy 2009;64:123–48.PubMedCrossRef

17.

Björkstén B, Clayton T, Ellwood P, et al. The ISAAC Phase III Study Group: Worldwide time trends for symptoms of rhinitis and conjunctivitis: phase III of the International Study of Asthma and Allergies in Childhood. Pediatr Allergy Immunol 2008;19:110–22.PubMedCrossRef

18.

Fok AO, Wong GW. What have we learned from ISAAC phase III in the Asia-Pacific rim? Curr Opin Allergy Clin Immunol 2009;9:116–22.PubMedCrossRef

19.

Nishima S, Chisaka H, Fujiwara T, et al. Allergy Prevalence Survey Group; West Japan Pediatric Allergy Association: surveys on the prevalence of pediatric bronchial asthma in Japan: a comparison between the 1982, 1992, and 2002 surveys conducted in the same region using the same methodology. Allergol Intern 2009;58:37–53.CrossRef

20.

Kusunoki T, Morimoto T, Nishikomori R, et al. Changing prevalence and severity of childhood allergic diseases in Kyoto, Japan, from 1996 to 2006. Allergol Intern 2009;58:543–8.CrossRef

21.

de Brito RC, da Silva GA, Motta ME, Brito MC. The association of rhinoconjunctivitis and asthma symptoms in adolescents. Rev Port Pneumol 2009;15:613–28.PubMed

22.

Bousquet J, Van Cauwenberge P, Khaltaev N; the Aria Workshop Group, World Health Organization. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001;108(5 Suppl):S147–334.PubMedCrossRef

23.

Björkstén B. The hygiene hypothesis: do we still believe in it? Nestle Nutr Workshop Ser Pediatr Program 2009;64:11–18; discussion 18–22, 251–257.PubMedCrossRef

24.

Kusel MM, de Klerk N, Holt PG, Sly PD. Antibiotic use in the first year of life and risk of atopic disease in early childhood. Clin Exp Allergy 2008;38:1921–28.PubMedCrossRef

25.

Mainardi T, Bielory L, Bielory B. Conserved domains (CDs) present in parasites and allergens. Ann Allergy Asthma Immunol 2009;102(Suppl 1):A59.

26.

Cooper PJ. Interactions between helminth parasites and allergy. Curr Opin Allergy Clin Immunol 2009;9:29–37.PubMedCrossRef

27.

Wördemann M, Diaz RJ, Heredia LM, et al. Association of atopy, asthma, allergic rhinoconjunctivitis, atopic dermatitis and intestinal helminth infections in Cuban children. Trop Med Int Health 2008;13:180–86.PubMedCrossRef

28.

Bager P, Arnved J, Ronborg S, et al. Trichuris suis ova therapy for allergic rhinitis: a randomized, double-blind, placebo-controlled clinical trial. J Allergy Clin Immunol 2009 Oct 2 (Epub ahead of print).

29.

Blaiss M. Evolving paradigm in the management of allergic rhinitis-associated ocular symptoms: role of intranasal corticosteroids. Curr Med Res Opin 2008;24:821–36.PubMedCrossRef

30.

Butrus S, Portela R. Ocular allergy: diagnosis and treatment. Ophthalmol Clin North Am 2005;18:485–92.PubMed

31.

Leonardi A, Motterle L, Bortolotti M. Allergy and the eye. Clin Exp Immunol 2008;153(Suppl 1):17–21.PubMedCrossRef

32.

Howarth PH, Salagean M, Dokic D. Allergic rhinitis: not purely a histamine-related disease. Allergy 2000;55(Suppl 64):7–16.PubMedCrossRef

33.

Choi SH, Bielory L. Late-phase reaction in ocular allergy. Curr Opin Allergy Clin Immunol 2008;8:438–44.PubMedCrossRef

34.

Naclerio RM, Proud D, Togias AG, et al. Inflammatory mediators in late antigen-induced rhinitis. N Engl J Med 1985;313:65–70.PubMed

35.

Bacon AS, Ahluwalia P, Irani AM, et al. Tear and conjunctival changes during the allergen-induced early- and late-phase responses. J Allergy Clin Immunol 2000;106:948–54.PubMedCrossRef

36.

Watelet JB, McGill JI, Church DS, Church MK. Allergic rhinitis and conjunctivitis: update on pathophysiology. In Allergy Frontiers: Clinical Manifestations. Edited by Pawankar R, Holgate ST, Rosenwasser LJ. Japan: Springer; 2009:1–23CrossRef

37.

• Baroody FM, Shenaq D, DeTineo M, et al. Fluticasone furoate nasal spray reduces the nasal-ocular reflex: a mechanism for the efficacy of topical steroids in controlling allergic eye symptoms. J Allergy Clin Immunol 2009;123:1342–48. In this clinical study, intranasal fluticasone furoate decreased nasal and ocular symptoms following a unilateral nasal allergen challenge. The results suggest that INS therapy may improve ocular allergy symptoms in part via suppression of the naso-ocular reflex.PubMedCrossRef

38.

Spangler DL, Abelson MB, Ober A, Gotnes PJ. Randomized, double-masked comparison of olopatadine ophthalmic solution, mometasone furoate monohydrate nasal spray, and fexofenadine hydrochloride tablets using the conjunctival and nasal allergen challenge models. Clin Ther 2003;25:2245–67.PubMedCrossRef

39.

Crampton HJ. Comparison of ketotifen fumarate ophthalmic solution alone, desloratadine alone, and their combination for inhibition of the signs and symptoms of seasonal ARC in the conjunctival allergen challenge model: a double-masked, placebo- and active-controlled trial. Clin Ther 2003;25:1975–87.PubMedCrossRef

40.

Sanke RF. Pseudonasolacrimal duct obstruction caused by nasal allergy. Ophthalmic Surg 1989;20:63–7.PubMed

41.

Bernstein DI, Levy AL, Hampel FC, et al. Treatment with intranasal fluticasone propionate significantly improves ocular symptoms in patients with seasonal allergic rhinitis. Clin Exp Allergy 2004;34:952–7.PubMedCrossRef

42.

Philip G, Baroody FM, Proud D, et al. The human nasal response to capsaicin. J Allergy Clin Immunol 1994;94:1035–45.PubMedCrossRef

43.

Zilstorff-Pedersen K. Quantitative measurements of the nasolacrimal reflex. Arch Otolaryngol 1965;81:457–62.PubMed

44.

Naclerio RM, Pinto J, deTineo M, Baroody FM. Elucidating the mechanism underlying the ocular symptoms associated with allergic rhinitis. Allergy Asthma Proc 2008;29:24–8.PubMedCrossRef

45.

Baroody FM, Foster KA, Markaryan A, et al. Nasal ocular reflexes and eye symptoms in patients with allergic rhinitis. Ann Allergy Asthma Immunol 2008;100:194–9.PubMedCrossRef

46.

Li J, Saito H, Crawford L, et al. Haemopoietic mechanisms in murine allergic upper and lower airway inflammation. Immunology 2005;114:386–96.PubMedCrossRef

47.

Saini S, Bloom DC, Bieneman A, et al. Systemic effects of allergen exposure on blood basophil IL-13 secretion and FcepsilonRIbeta. J Allergy Clin Immunol 2004;114:768–74.PubMedCrossRef

48.

Denburg JA, Sehmi R, Saito H, et al. Systemic aspects of allergic disease: bone marrow responses. J Allergy Clin Immunol 2000;106(5 Suppl):S242–46.PubMedCrossRef

49.

Naclerio R. Intranasal corticosteroids reduce ocular symptoms associated with allergic rhinitis. Otolaryngol Head Neck Surg 2008;38:129–39.CrossRef

50.

Yáñez A, Rodrigo GJ. Intranasal corticosteroids versus topical H1 receptor antagonists for the treatment of allergic rhinitis: a systematic review with meta-analysis. Ann Allergy Asthma Immunol 2002;89:479–84.PubMedCrossRef

51.

Weiner JM, Abramson MJ, Puy RM. Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: systematic review of randomised controlled trials. BMJ 1998;317:1624–29.PubMed

52.

Kaszuba SM, Baroody FM, deTineo M, et al. Superiority of an intranasal corticosteroid compared with an oral antihistamine in the as-needed treatment of seasonal allergic rhinitis. Arch Intern Med 2001;161:2581–87.PubMedCrossRef

53.

Condemi J, Schulz R, Lim J. Triamcinolone acetonide aqueous nasal spray versus loratadine in seasonal allergic rhinitis: efficacy and quality of life. Ann Allergy Asthma Immunol 2000;84:533–8.PubMedCrossRef

54.

Kaliner MA, Storms W, Tilles S, et al. Comparison of olopatadine 0.6% nasal spray versus fluticasone propionate 50 mcg in the treatment of seasonal allergic rhinitis. Allergy Asthma Proc 2009;30:255–62.PubMedCrossRef

55.

Shah SR, Nayak A, Ratner P, et al. Effects of olopatadine hydrochloride nasal spray 0.6% in the treatment of seasonal allergic rhinitis: a phase III, multicenter, randomized, double-blind, active- and placebo-controlled study in adolescents and adults. Clin Ther 2009;31:99–107.PubMedCrossRef

56.

Bousquet J, Khaltaev N, Cruz AA, et al.; the World Health Organization, GA(2)LEN, AllerGen. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN, and AllerGen). Allergy 2008;63(Suppl 86):8–160.PubMedCrossRef

57.

• Bernstein JA, Prenner B, Ferguson BJ, et al. Double-blind, placebo-controlled trial of reformulated azelastine nasal spray in patients with seasonal allergic rhinitis. Am J Rhinol Allergy 2009;23:512–7. This was a randomized clinical trial comparing a new sucralose-containing formulation of intranasal azelastine with the original formulation. Improvements in nasal symptoms were comparable between the two formulations.PubMedCrossRef

58.

Lumry WR. A review of the preclinical and clinical data of newer intranasal steroids used in the treatment of allergic rhinitis. J Allergy Clin Immunol 1999;104:150–58.CrossRef

59.

Rosenwasser LJ, Mahr T, Abelson MB, et al. A comparison of olopatadine 0.2% ophthalmic solution versus fluticasone furoate nasal spray for the treatment of allergic conjunctivitis. Allergy Asthma Proc 2008;29:644–53.PubMedCrossRef

60.

• Andrews CP, Martin BG, Jacobs RL, et al. Fluticasone furoate nasal spray is more effective than fexofenadine for nighttime symptoms of seasonal allergy. Allergy Asthma Proc 2009;30:128–38. This article reports the results of two similarly designed clinical studies comparing the INS fluticasone furoate and the oral antihistamine fexofenadine as therapies for the nocturnal symptoms of seasonal allergy. Fluticasone furoate demonstrated superiority to fexofenadine and placebo on measures of nasal and ocular symptomatology.PubMedCrossRef

61.

• Anolik R, Pearlman D, Teper A, Gates D. Mometasone furoate improves nasal and ocular symptoms of seasonal allergic rhinitis in adolescents. Allergy Asthma Proc 2009;30:406–412. This was a post hoc analysis of data on adolescents who participated in a prospective study of the INS mometasone furoate in SAR. Mometasone furoate demonstrated superiority to placebo in the treatment of nasal and ocular allergic symptoms.PubMedCrossRef

62.

Bachert C, Kuna P, Sanquer F, et al.; Bilastine International Working Group. Comparison of the efficacy and safety of bilastine 20 mg vs desloratadine 5 mg in seasonal allergic rhinitis patients. Allergy 2009;64:158–65.PubMedCrossRef

63.

Kuna P, Bachert C, Nowacki Z, et al.; the Bilastine International Working Group. Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: a randomized, double-blind, parallel-group study. Clin Exp Allergy 2009;39:1338–47.PubMedCrossRef

64.

Abelson MB, Torkildsen GL, Williams JL, et al. Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: a phase III, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen challenge assessment in adults and children. Clin Ther 2009;31:1908–21.PubMedCrossRef

65.

Hashiguchi K, Tang H, Fujita T, et al. Bepotastine besilate OD tablets suppress nasal symptoms caused by Japanese cedar pollen exposure in an artificial exposure chamber (OHIO Chamber). Expert Opin Pharmacother 2009;10:523–9.PubMedCrossRef

66.

LaForce C. Use of nasal steroids in managing allergic rhinitis. J Allergy Clin Immunol 1999;103:S388–94.PubMedCrossRef

67.

Daley-Yates PT, Kunka RL, Yin Y, et al. Bioavailability of fluticasone propionate and mometasone furoate aqueous nasal sprays. Eur J Clin Pharmacol 2004;60:265–8.PubMedCrossRef

68.

Allen A, Down G, Newland A, et al. Absolute bioavailability of intranasal fluticasone furoate in healthy subjects. Clin Ther 2007;29:1415–20.PubMedCrossRef

69.

Bross-Soriano D, Hanenberg-Milver C, Schimelmitz-Idi J, et al. Effects of three nasal topical steroids in the intraocular pressure compartment. Otolaryngol Head Neck Surg 2004;130:187–91.PubMedCrossRef

70.

Banov CH, Woehler TR, LaForce CF, et al. Once daily intranasal fluticasone propionate is effective for perennial allergic rhinitis. Ann Allergy 1994;73:240–46.PubMed

71.

van As A, Bronsky EA, Dockhorn RJ, et al. Once daily fluticasone propionate is as effective for perennial allergic rhinitis as twice daily beclomethasone dipropionate. J Allergy Clin Immunol 1993;91:1146–54.PubMedCrossRef

72.

Dibildox J. Safety and efficacy of mometasone furoate aqueous nasal spray in children with allergic rhinitis: results of recent clinical trials. J Allergy Clin Immunol 2001;108(1 Suppl):S54–8.PubMedCrossRef

73.

Ratner PH, Meltzer EO, Teper A. Mometasone furoate nasal spray is safe and effective for 1-year treatment of children with perennial allergic rhinitis. Int J Pediatr Otorhinolaryngol 2009;73:651–7.PubMedCrossRef

74.

Maspero JF, Rosenblut A, Finn A Jr, et al. Safety and efficacy of fluticasone furoate in pediatric patients with perennial allergic rhinitis. Otolaryngol Head Neck Surg 2008;138:30–37.PubMedCrossRef

75.

Meltzer EO, Hampel FC, Ratner PH, et al. Safety and efficacy of olopatadine hydrochloride nasal spray for the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2005;95:600–606.PubMedCrossRef

76.

Salib RJ, Howarth PH. Safety and tolerability profiles of intranasal antihistamines and intranasal corticosteroids in the treatment of allergic rhinitis. Drug Safety 2003;26:863–93.PubMedCrossRef

77.

Pipkorn U, Proud D, Lichtenstein LM, et al. Inhibition of mediator release in allergic rhinitis by pre-treatment with topical glucocorticosteroids. N Engl J Med 1987;316:1506–510.PubMedCrossRef

78.

Stelmach R, do Patrocínio M, Nunes M, et al. Effect of treating allergic rhinitis with corticosteroids in patients with mild-to-moderate persistent asthma. Chest 2005;128:3140–47.PubMedCrossRef

79.

Reinartz SM, Overbeek SE, KleinJan A, et al. Desloratadine reduces systemic allergic inflammation following nasal provocation in allergic rhinitis and asthma patients. Allergy 2005;60:1301–307.PubMedCrossRef

80.

DeWester J, Philpot EE, Westlund RE, et al. The efficacy of intranasal fluticasone propionate in the relief of ocular symptoms associated with seasonal allergic rhinitis. Allergy Asthma Proc 2003;24:331–7.PubMed

81.

Bielory L. Ocular symptom reduction in patients with seasonal allergic rhinitis treated with the intranasal corticosteroid mometasone furoate. Ann Allergy Asthma Immunol 2008;100:272–9.PubMedCrossRef

82.

Settipane G, Korenblat PE, Winder J, et al. Triamcinolone acetonide aqueous nasal spray in patients with seasonal ragweed allergic rhinitis: a placebo-controlled, double-blind study. Clin Ther 1995;17:252–63.PubMedCrossRef

83.

Tinkelman D, Falliers C, Gross G, et al. Multicenter evaluation of triamcinolone acetonide nasal aerosol in the treatment of adult patients with seasonal allergic rhinitis. Ann Allergy 1990;64:234–40.PubMed

84.

Ciprandi G, Canonica WG, Grosclaude M, et al. Effects of budesonide and fluticasone propionate in a placebo-controlled study on symptoms and quality of life in seasonal allergic rhinitis. Allergy 2002;57:586–91.PubMedCrossRef

85.

Scadding GK, Keith PK. Fluticasone furoate nasal spray consistently and significantly improves both the nasal and ocular symptoms of seasonal allergic rhinitis: a review of the clinical data. Expert Opin Pharmacother 2008;9:2707–715.PubMedCrossRef

86.

Keith PK, Scadding GK. Are intranasal corticosteroids all equally consistent in managing ocular symptoms of seasonal allergic rhinitis? Curr Med Res Opin 2009;258:2021–41.CrossRef

87.

Katelaris CH, Bielory L. Evidence-based study design in ocular allergy trials. Curr Opin Allergy Clin Immunol 2008;8:484–8.PubMedCrossRef

88.

Vasar M, Houle PA, Douglass JA, et al. Fluticasone furoate nasal spray: effective monotherapy for symptoms of perennial allergic rhinitis in adults/adolescents. Allergy Asthma Proc 2008;29:313–21.PubMedCrossRef

89.

Bielory L. A meta-analysis of the impact of mometasone furoate nasal spray on individual ocular symptoms of allergic rhinitis [poster P511]. Poster presented at the 2009 American Academy of Allergy, Asthma & Immunology Annual Meeting. Washington, DC; March 13–17, 2009.

90.

Nathan RA, Berger W, Yang W, et al. Effect of once-daily fluticasone furoate nasal spray on nasal symptoms in adults and adolescents with perennial allergic rhinitis. Ann Allergy Asthma Immunol 2008;100:497–505.PubMedCrossRef

91.

Mandl M, Nolop K, Lutsky BN; the 194-079 Study Group. Comparison of once daily mometasone furoate (Nasonex) and fluticasone propionate aqueous nasal sprays for the treatment of perennial rhinitis. Ann Allergy Asthma Immunol 1997;79:370–78.PubMedCrossRef

92.

Abelson MB, Gomes PJ, Vogelson CT, et al. Effects of a new formulation of olopatadine ophthalmic solution on nasal symptoms relative to placebo in two studies involving subjects with allergic conjunctivitis or rhinoconjunctivitis. Curr Med Res Opin 2005;21:683–91.PubMedCrossRef

93.

Horak F, Berger UE, Menapace R, et al. Dose-dependent protection by azelastine eye drops against pollen-induced allergic conjunctivitis. a double-blind, placebo-controlled study. Arzneimittelforschung 1998;48:379–84.PubMed

94.

Gow JA, Williams JI, McNamara TR, Gomes PJ, Abelson MB. Bepreve™ 1.5% Reduces nasal congestion for at least 16 hours: an analysis of integrated data from two phase 3 conjunctival allergen challenge (CAC) clinical trials. J Allergy Clin Immunol 2010;125(2):AB38.

95.

Schatz M. A survey of the burden of allergic rhinitis in the USA. Allergy 2007;62(Suppl 85):9–16.PubMedCrossRef

96.

Canonica GW, Bousquet J, Mullol J, et al. A survey of the burden of allergic rhinitis in Europe. Allergy 2007;62(Suppl 85):17–25.PubMedCrossRef

97.

Calderon MA, Alves B, Jacobson M, et al. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev 2007;1:CD001936.

98.

Patel P, Roland PS, Marple BF, et al. An assessment of the onset and duration of action of olopatadine nasal spray. Otolaryngol Head Neck Surg 2007;137:918–24.PubMedCrossRef

99.

Ratner PH, Hampel FC, Amar NJ, et al. Safety and efficacy of olopatadine hydrochloride nasal spray for the treatment of seasonal allergic rhinitis to mountain cedar. Ann Allergy Asthma Immunol 2005;95:474–9.PubMedCrossRef

100.

Lee TA, Pickard S. Meta-analysis of azelastine nasal spray for the treatment of allergic rhinitis. Pharmacotherapy 2007;27:852–9.PubMedCrossRef

101.

Berlin JM, Golden SJ, Teets S, et al. Efficacy of a steroid nasal spray compared with an antihistamine nasal spray in the treatment of perennial allergic rhinitis. J Am Osteopath Assoc 2000;100(7 Suppl):S8–13.PubMed

102.

Charpin D, Godard P, Garay RP, et al. A multicenter clinical study of the efficacy and tolerability of azelastine nasal spray in the treatment of seasonal allergic rhinitis: a comparison with oral cetirizine. Eur Arch Otorhinolaryngol 1995;252:455–8.PubMedCrossRef

103.

LaForce C, Dockhorn RJ, Prenner BM, et al. Safety and efficacy of azelastine nasal spray (Astelin NS) for seasonal allergic rhinitis: a 4-week comparative multicenter trial. Ann Allergy Asthma Immunol 1996;76:181–8.PubMedCrossRef

104.

Storms WW, Pearlman DS, Chervinsky P, et al. Efectiveness of azelastine nasal solution in seasonal allergic rhinitis. Ear Nose Throat J 1994;73:382–94.PubMed

105.

Ratner PH, Ehrlich PM, Fineman SM, et al. Use of intranasal cromolyn sodium for allergic rhinitis. Mayo Clin Proc 2002;77:350–54.PubMedCrossRef

106.

Handelman NI, Friday GA, Schwartz HJ, et al. Cromolyn sodium nasal solution in the prophylactic treatment of pollen-induced seasonal allergic rhinitis. J Allergy Clin Immunol 1977;59:237–42.PubMedCrossRef

107.

Meltzer EO; for the NasalCrom Study Group. Efficacy and patient satisfaction in the treatment of seasonal allergic rhinitis: a placebo-controlled study. Clin Ther 2002;24:942–52.PubMedCrossRef

108.

Fokkens WJ, Jogi R, Reinartz S, et al. Once daily fluticasone furoate nasal spray is effective in seasonal allergic rhinitis caused by grass pollen. Allergy 2007;62:1078–84.PubMedCrossRef

109.

Martin BG, Ratner PH, Hampel FC, et al. Optimal dose selection of fluticasone furoate nasal spray for the treatment of seasonal allergic rhinitis in adults and adolescents. Allergy Asthma Proc 2007;28:216–25.PubMedCrossRef

110.

Kaiser HB, Naclerio RM, Given J, et al. Fluticasone furoate nasal spray: a single treatment option for the symptoms of seasonal allergic rhinitis. J Allergy Clin Immunol 2007;119:1430–37.PubMedCrossRef

111.

Penagos M, Compalati E, Tarantini F, et al. Efficacy of mometasone furoate nasal spray in the treatment of allergic rhinitis. Meta-analysis of randomized, double-blind, placebo-controlled, clinical trials. Allergy 2008;63:1280–91.PubMedCrossRef

112.

Schenkel E, LaForce C, Gates D. Mometasone furoate nasal spray in seasonal allergic rhinitis: effective in relieving ocular symptoms. Allergy Clin Immunol Int J World Allergy Org 2007;19:50–53.CrossRef

113.

Lumry W, Hampel F, LaForce C, et al. A comparison of once-daily triamcinolone acetonide aqueous and twice-daily beclomethasone dipropionate. Allergy Asthma Proc 2003;24:203–210.PubMed

114.

Gross G, Jacobs RL, Woodworth TH, et al. Comparative efficacy, safety, and effect on quality of life of triamcinolone acetonide and fluticasone propionate aqueous nasal sprays in patients with fall seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2002;89:56–62.PubMedCrossRef

115.

Berger WE, Kaiser H, Gawchik SM, et al. Triamcinolone acetonide aqueous nasal spray and fluticasone propionate are equally effective for relief of nasal symptoms in patients with seasonal allergic rhinitis. Otolaryngol Head Neck Surg 2003;129:16–23.PubMedCrossRef

116.

Schoenwetter W, Lim J. Comparison of intranasal triamcinolone acetonide with oral loratadine for the treatment of patients with seasonal allergic rhinitis. Clin Ther 1995;17:479–92.PubMedCrossRef

117.

LaForce C, van Bavel J, Meltzer EO, Wingertzahn MA. Efficacy and safety of ciclesonide hydrofluoroalkane nasal aerosol once daily for the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2009;103:166–73.PubMedCrossRef

118.

Chervinsky P, Kunjibettu S, Miller DL, et al. Long-term safety and efficacy of intranasal ciclesonide in adult and adolescent patients with perennial allergic rhinitis. Ann Allergy Asthma Immunol 2007;99:69–76.PubMedCrossRef

119.

Ratner PH, Wingertzahn MA, van Bavel JH, et al. Effectiveness of ciclesonide nasal spray in the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2006;97:657–63.PubMedCrossRef

120.

Meltzer EO, Kunjibettu S, Hall N, et al. Efficacy and safety of ciclesonide, 200 microg once daily, for the treatment of perennial allergic rhinitis. Ann Allergy Asthma Immunol 2007;98:175–81.PubMedCrossRef

121.

Ratner PH, Wingertzahn MA, van Bavel JH, et al. Efficacy and safety of ciclesonide nasal spray for the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol 2006;118:1142–48.PubMedCrossRef

122.

Morgan MM, Khan DA, Nathan RA. Treatment for allergic rhinitis and chronic idiopathic urticaria: focus on oral antihistamines. Ann Pharmacother 2005;39:2056–64.PubMedCrossRef

123.

Meltzer EO, Prenner BM, Nayak A; Desloratadine Study Group. Efficacy and tolerability of once-daily 5 mg desloratadine, an H1-receptor antagonist, in patients with seasonal allergic rhinitis: assessment during the spring and fall allergy seasons. Clin Drug Invest 2001;21:25–32.CrossRef

124.

Goodhue K, Depelteau D, Welch D, et al. Evaluation of the anti-allergic and anti- inflammatory effects of multiple doses of desloratadine on conjunctival allergen challenge-induced ocular signs and symptoms [poster]. Poster presented at the 2006 Association for Research in Vision and Ophthalmology Annual Meeting. Fort Lauderdale, FL; April 30–May 4, 2006.

125.

Casale TB, Andrade C, Qu R. Safety and efficacy of once-daily fexofenadine HCl in the treatment of autumn seasonal allergic rhinitis. Allergy Asthma Proc 1999;20:193–8.PubMedCrossRef

126.

Leynadier F, Mees K, Arendt C, Pinelli ME. Efficacy and safety of levocetirizine in seasonal allergic rhinitis. Acta Otorhinolaryngol Belg 2001;55:305–12.PubMed

127.

Joint Task Force on Practice Parameters. Attaining optimal asthma control: a practice parameter. J Allergy Clin Immunol 2005;116:S3–11.CrossRef

128.

Wallace DV, Dykewicz MS. The diagnosis and management of rhinitis: an updated practice parameter. J Allergy Clin Immunol 2008;122:S1–84.PubMedCrossRef

Titel: Allergic Conjunctivitis and the Impact of Allergic Rhinitis
verfasst von: Leonard Bielory
Publikationsdatum: 01.03.2010
Verlag: Current Science Inc.
Erschienen in: Current Allergy and Asthma Reports / Ausgabe 2/2010
Print ISSN: 1529-7322
Elektronische ISSN: 1534-6315
DOI: https://doi.org/10.1007/s11882-010-0087-1

Neu im Fachgebiet HNO

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Hörschwäche erhöht Demenzrisiko unabhängig von Beta-Amyloid

29.05.2024 Hörstörungen Nachrichten

Hört jemand im Alter schlecht, nimmt das Hirn- und Hippocampusvolumen besonders schnell ab, was auch mit einem beschleunigten kognitiven Abbau einhergeht. Und diese Prozesse scheinen sich unabhängig von der Amyloidablagerung zu ereignen.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Allergic Conjunctivitis and the Impact of Allergic Rhinitis

Abstract

Neu im Fachgebiet HNO

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Hörschwäche erhöht Demenzrisiko unabhängig von Beta-Amyloid

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

Update HNO

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2010

Vasomotor Rhinitis

Congestion and Sleep Impairment in Allergic Rhinitis

The Nose and its Relationship to the Eyes

Occupational Rhinitis

Historical, Pathophysiological, and Therapeutic Aspects of Vidian Neurectomy

Occupational Rhinitis and Asthma: Where Do We Stand, Where Do We Go?

Neu im Fachgebiet HNO

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Hörschwäche erhöht Demenzrisiko unabhängig von Beta-Amyloid

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

Update HNO